Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
TRAC Biologics Sequence Review Report 2026: T cell receptor alpha chain constant Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TRAC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TBXA2R Biologics Sequence Review Report 2026: Thromboxane A2 receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TBXA2R protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TIE1 Biologics Sequence Review Report 2026: Tyrosine-protein kinase receptor Tie-1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TIE1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TARM1 Biologics Sequence Review Report 2026: T-cell-interacting, activating receptor on myeloid cells protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TARM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TACR3 Biologics Sequence Review Report 2026: Neuromedin-K receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TACR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TACR1 Biologics Sequence Review Report 2026: Substance-P receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TACR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TACR2 Biologics Sequence Review Report 2026: Substance-K receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TACR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TAAR5 Biologics Sequence Review Report 2026: Trace amine-associated receptor 5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TAAR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SSTR4 Biologics Sequence Review Report 2026: Somatostatin receptor type 4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of SSTR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SSTR5 Biologics Sequence Review Report 2026: Somatostatin receptor type 5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of SSTR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SSTR3 Biologics Sequence Review Report 2026: Somatostatin receptor type 3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of SSTR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
SSTR1 Biologics Sequence Review Report 2026: Somatostatin receptor type 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of SSTR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
206
207
208
209
210
>>
1872
>